



FDA grants approval to Rhythm Pharmaceuticals' IMCIVREE as a label expansion to treat acquired hypothalamic obesity in patients aged 4 years and older

(FDA, Approval)



Novo Nordisk's WEGOVY HD 7.2 mg gains FDA approval to reduce excess body weight and maintain long-term weight reduction, based on results from the STEP UP trial

(FDA, Approval)



Johnson & Johnson receives FDA approval for ICOTYDE, an IL-23R-targeted oral peptide for treating moderate-to-severe plaque psoriasis

(FDA, Approval)



FDA approves GSK's LYNAVOY, an IBAT inhibitor, to treat cholestatic pruritus in patients with primary biliary cholangitis

(FDA, Approval)





(EU, Approval)
EC approves AstraZeneca's IMFINZI as the first and only perioperative immunotherapy for early gastric and gastroesophageal junction cancer



(Health Canada, Approval)
Health Canada approves Celltrion's autoinjector formulation of STEQEYMA to treat autoimmune diseases, enabling wider range of treatment options



(FDA, Breakthrough Therapy)
Sanofi gains Breakthrough Therapy designation from the FDA for its investigational oral glucosylceramide synthase inhibitor, venglustat, to treat neurological manifestations of type 3 Gaucher disease



(NMPA, Priority Review)
Gyre Therapeutics obtains priority review from China's NMPA for its F35I to treat chronic hepatitis B-induced liver fibrosis



SANDOZ

Sandoz partners with Samsung Bioepis to develop and commercialize up to five biosimilar assets, including vedolizumab

(Partnership)



Pfizer's Phase 3 TALAPRO-3 trial with the combination of TALZENNA plus XTANDI, met its primary endpoint, improving radiographic progression-free survival in metastatic castration-sensitive prostate cancer

(Phase 3, Results)

